Is NCT07482176 recruiting in Sun City, AZ?

Yes, NCT07482176 is currently recruiting participants at its Sun City, AZ location. This neovascular age-related macular degeneration (namd) clinical trial is actively enrolling qualified participants.

Is participation in this Sun City clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trial in Sun City, AZ

Q: How do I join the neovascular age-related macular degeneration (namd) clinical trial in Sun City?

To join this clinical trial in Sun City, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Neovascular Age-Related Macular Degeneration (nAMD) Study in Sun City

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.

Sponsor: Adverum Biotechnologies, Inc.

Who Can Participate

Inclusion Criteria

Able and willing to provide informed consent (or have a legally authorized representative who is able and willing to provide informed consent) prior to any study assessments and procedures and comply with the study requirements and visits.

Male or female with a diagnosis of CNV secondary to nAMD in the study eye, with nAMD disease activity at Screening Visit 1.

At least 50 years old at Screening Visit 1.

An ETDRS BCVA letter score of 35 - 78 (approximate Snellen equivalent of 20/200 to 20/32) in the study eye at Screening Visit 1.

Demonstrated a meaningful anatomic response to anti-VEGF therapy during screening.

Able to reliably use eye drops per protocol.

Exclusion Criteria

General Exclusion Criteria

History of a medical condition giving reasonable suspicion of a condition that contraindicates the use of Ixo-vec, compromises the participant's ability to comply with the planned study activities, or that might affect the interpretation of the results of the study or render the participant at high risk for treatment complications in the opinion of the Investigator. History of severe coronavirus disease (COVID-19) infection may meet this exclusion criterion if, in the opinion of the Investigator, it is likely to lead to any important complications.

Received any prior gene therapy.

Prior treatment with any non-gene therapy investigational medicinal product (IMP) or medical device in the study eye within 3 months of Screening Visit 1 or 5 half-lives of the IMP prior to dosing with Ixo-vec, whichever is longer.

Female participants who are pregnant or breastfeeding or who intend to become pregnant or breastfeed in the future.

History or evidence of any of the following cardiovascular diseases:

Myocardial infarction in the 6-month period prior to Week 1.

Uncontrolled hypertension defined as systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg during screening.

Stroke in the 6-month period prior to Week 1.

History of ongoing bleeding disorders. The use of aspirin or other anticoagulants (e.g., Factor Xa inhibitors) is permitted.

Use of systemic immunosuppressive drugs within 90 days prior to Screening Visit 1. Short courses of oral corticosteroids are permitted, as well as any inhaled, intra-articular, nasal or dermal steroid use.

Evidence of poorly controlled diabetes or glycated hemoglobin (HbA1c) ≥ 8.0% during screening. Ocular Exclusion Criteria

Any active ocular or periocular infection in the study eye from Screening Visit 1.

History or evidence of the following in the study eye:

Intraocular or refractive surgery within 5 months prior to Week 1.

Any previous penetrating keratoplasty or vitrectomy.

Any previous panretinal photocoagulation.

Any previous submacular surgery, other surgical intervention (including port delivery system) or laser treatment for age-related macular degeneration.

Any history or evidence of retinal detachment (with or without repair) or retinal pigment epithelium rip/tear in the study eye, as determined by the Investigator during screening or at Week 1.

Uncontrolled ocular hypertension or glaucoma in the study eye from Screening Visit 1 to Week 1 or current use of ≥ 2 intraocular pressure (IOP) lowering medications or normal tension glaucoma/suspect in the study eye or history of any of the following procedures in the study eye prior to Week 1:

Incisional glaucoma surgery (i.e., glaucoma drainage implant/shunt or trabeculectomy)

Ocular angle-based surgery (i.e., goniotomy or canaloplasty)

Minimally Invasive Glaucoma Surgery (MIGS) in the study eye.

Angle-based glaucoma surgery (e.g., Argon or Selective Laser Trabeculoplasty)

Any history of IOP elevation related to topical steroid administration in either eye.

Any history of uveitis or inflammation (grade trace or above) except mild anticipated post operative inflammation that resolved in either eye.

Any history of treatment with complement inhibitors for geographic atrophy in the study eye.

Known history of ocular herpes simplex virus, varicella-zoster virus, or cytomegalovirus, including viral uveitis, retinitis, or keratitis in either eye.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sun City?

Yes, this clinical trial (NCT07482176) has an active research site in Sun City, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neovascular Age-Related Macular Degeneration (nAMD) Treatment Options in Sun City, AZ

If you're searching for neovascular age-related macular degeneration (namd) treatment options in Sun City, AZ, this clinical trial (NCT07482176) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sun City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neovascular age-related macular degeneration (namd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neovascular age-related macular degeneration (namd) clinical trials near you to find additional studies recruiting in your area.

Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trial in Sun City, AZ

Expert Care in Sun City

IRB Approved

No-Cost Care

Apply for This Sun City Location

Why Participate?

Simple Process